Limits...
Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.

Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ, Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Stu - Heart (2014)

Bottom Line: The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.

View Article: PubMed Central - PubMed

Affiliation: BresMed, Sheffield, UK.

Show MeSH

Related in: MedlinePlus

Deterministic sensitivity analysis tornado plots. CV, cardiovascular; HF, heart failure; QALY, quality-adjusted life year.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215293&req=5

HEARTJNL2014305673F2: Deterministic sensitivity analysis tornado plots. CV, cardiovascular; HF, heart failure; QALY, quality-adjusted life year.

Mentions: A range of deterministic sensitivity analyses were carried out to test the robustness of the model projections by varying key inputs and assumptions. One-way parameter sensitivity analyses were performed by varying each parameter within its likely range using the 95% CIs of the parameter distributions (figure 2). In addition, a range of scenario analyses were conducted.


Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.

Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ, Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Stu - Heart (2014)

Deterministic sensitivity analysis tornado plots. CV, cardiovascular; HF, heart failure; QALY, quality-adjusted life year.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215293&req=5

HEARTJNL2014305673F2: Deterministic sensitivity analysis tornado plots. CV, cardiovascular; HF, heart failure; QALY, quality-adjusted life year.
Mentions: A range of deterministic sensitivity analyses were carried out to test the robustness of the model projections by varying key inputs and assumptions. One-way parameter sensitivity analyses were performed by varying each parameter within its likely range using the 95% CIs of the parameter distributions (figure 2). In addition, a range of scenario analyses were conducted.

Bottom Line: The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.

View Article: PubMed Central - PubMed

Affiliation: BresMed, Sheffield, UK.

Show MeSH
Related in: MedlinePlus